Conestat Alfa

Phase 3Small molecule

UUniversity Hospital, Basel, Switzerland

Conestat Alfa is one of 77 small molecule programs targeting Angioedema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

COVID-19Active, not recruiting

NephropathyActive, not recruiting

AngioedemaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Conestat Alfa

UUniversity Hospital, Basel, Switzerland

Phase 3

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Alnylam Pharmaceuticals

Activella

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 9

SARS-COV-2 VACCINE

Moderna

Preclinical

2 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT04414631·80 enrolled

Nephropathy1 trial

Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02869347·80 enrolled

Angioedema1 trial

Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema

Not yet recruiting·UUniversity of Cincinnati·Phase 3·NCT06679426·24 enrolled

Prevention1 trial

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT05145283·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Conestat Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Conestat Alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Conestat Alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Basel, Switzerland

Conestat Alfa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Nephropathy1 trial

Angioedema1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News